Probiotics in Septic AKI
Trial question
What is the role of probiotics in patients with AKI related to sepsis?
Study design
Single center
Double blinded
RCT
Population
Characteristics of study participants
51.0% female
49.0% male
N = 92
92 patients (47 female, 45 male).
Inclusion criteria: patients with AKI associated with sepsis.
Key exclusion criteria: pregnancy; CKD KDIGO stages 4-5 or on chronic dialysis; kidney transplant; no informed consent.
Interventions
N=48 probiotics (2 capsules per os or through an enteral tube every 24 hours for 7 consecutive days).
N=44 placebo (matching placebo for 7 consecutive days).
Primary outcome
Rate of kidney function recovery by day 7
50%
48%
50.0 %
37.5 %
25.0 %
12.5 %
0.0 %
Probiotics
Placebo
No significant
difference ↔
No significant difference in the rate of kidney function recovery by day 7 (50% vs. 48%; HR 0.93, 95% CI 0.52 to 1.68).
Secondary outcomes
No significant difference in death (37% vs. 61%; HR 0.56, 95% CI 0.32 to 1.04).
No significant difference in kidney replacement therapy (26% vs. 12%; RR 2.19, 95% CI 0.84 to 5.72).
Significantly greater reduction in urea values (74 mg/dL vs. 21 mg/dL; AD 53 mg/dL, 95% CI 2.33 to 103.67).
Safety outcomes
No significant difference in adverse events.
Conclusion
In patients with AKI associated with sepsis, probiotics were not superior to placebo with respect to the rate of kidney function recovery by day 7.
Reference
Jonathan S Chávez-Íñiguez, Miguel Ibarra-Estrada, Alejandro Martínez Gallardo-González et al. Probiotics in septic acute kidney injury, a double blind, randomized control trial. Ren Fail. 2023;45(2):2260003.
Open reference URL